What are the typical cutaneous manifestations of psoriasis, the recommended treatment options, and is swelling (e.g., psoriatic arthritis) associated?

Psoriasis Appearance, Treatment, and Swelling

Psoriasis typically appears as raised, red patches covered with thick, silvery-white scales (erythematous scaly plaques), and yes, swelling is commonly involved—either as joint swelling from psoriatic arthritis (affecting 30-33% of psoriasis patients) or as dactylitis (sausage-like swelling of fingers/toes). 1, 2

What Psoriasis Looks Like

The classic cutaneous presentation includes:

• Erythematous (red) plaques with silvery-white scales that are well-demarcated 2
• Common locations: elbows, knees, scalp, lower back, but can occur anywhere
• Nail involvement in 80-90% of psoriatic arthritis patients, showing pitting and onycholysis (nail separation) 3
• Specific phenotypes that matter clinically:
  • Scalp psoriasis
  • Palmoplantar involvement (hands and feet)
  • Inverse psoriasis (skin folds)
  • Nail psoriasis (strongly associated with joint disease) 4

Swelling: A Critical Component

Yes, swelling is a major feature of psoriatic disease through two mechanisms:

Psoriatic Arthritis (PsA)

• Develops in 30-33% of psoriasis patients, typically 10-11 years after skin disease onset 1
• Presents with joint swelling, redness, warmth in addition to pain 1
• Dactylitis: sausage-like swelling of entire fingers or toes from inflammation of small joints plus surrounding soft tissue 1
• Enthesitis: swelling at tendon/ligament insertion points into bone 1
• Can affect peripheral joints (hands, feet, knees, wrists, elbows) or spine 1, 3

Critical pitfall: Joint complaints (arthralgia, stiffness, swelling) occur in up to 17% of psoriasis patients, requiring close monitoring to detect early PsA 1. Uncontrolled arthritis causes permanent joint damage in 50% of patients, making early detection imperative 1.

Treatment Approach

For Mild Cutaneous Psoriasis

Start with topical therapies 2, 5:

• Topical corticosteroids
• Vitamin D analogues
• Topical calcineurin inhibitors
• Newer options: topical PDE4 inhibitors, aryl hydrocarbon receptor agonists

For Moderate-to-Severe Psoriasis or Any PsA

Escalate to systemic therapy 2, 5:

Oral small molecules:

• Methotrexate
• Apremilast (PDE4 inhibitor)
• JAK inhibitors (tofacitinib)
• Deucravacitinib (TYK2 inhibitor)
• Cyclosporine or acitretin (less commonly used)

Biologic therapies (highly effective for both skin and joints) 3, 2, 5:

• IL-17 inhibitors (target IL-17A or IL-17RA)
• IL-23 inhibitors (target IL-23 pathway)
• IL-12/23 inhibitors
• TNF inhibitors
• CTLA4-Ig (abatacept)

For Mild PsA Flare-Ups

• NSAIDs for symptomatic relief 5
• Intra-articular glucocorticoid injections 5

Treatment Algorithm

1. Screen every psoriasis patient for joint symptoms at each visit (arthralgia, stiffness, swelling, dactylitis) 1
2. If only skin disease and mild: topical therapy
3. If moderate-severe skin OR any joint involvement: systemic therapy (oral small molecules or biologics)
4. Treat both skin and joints simultaneously—the same systemic agents work for both domains 3, 5
5. Use treat-to-target strategy aiming for disease remission 3

Critical Warnings

Screen for comorbidities that increase morbidity and mortality 1, 2:

• Cardiovascular disease (increased risk)
• Metabolic syndrome and diabetes
• Mental health disorders
• Inflammatory bowel disease
• Implement cardiovascular risk reduction strategies

Do not delay treatment of suspected PsA—permanent joint destruction occurs without early intervention 1. The 2018 ACR/NPF guidelines emphasize early identification and treatment initiation 3.

Multidisciplinary care is essential: Dermatologists must screen for arthritis, and rheumatologists should be involved when joint disease is suspected 1, 6. Nail psoriasis is a particular red flag for PsA development 6.